Alfredo Campennì1, Ernesto Amato2, Riccardo Laudicella2, Angela Alibrandi3, Davide Cardile2, Salvatore Antonio Pignata2, Francesco Trimarchi4, Rosaria Maddalena Ruggeri5, Lucrezia Auditore2, Sergio Baldari2. 1. Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, Italy. acampenni@unime.it. 2. Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, Italy. 3. Department of Economical, Business and Environmental Sciences and Quantitative Methods, University of Messina, Messina, Italy. 4. Accademia Peloritana dei Pericolanti at the University of Messina, Messina, Italy. 5. Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Messina, Messina, Italy.
Abstract
PURPOSE: In DTC patients, 131-radioiodine therapy has routinely been used for many years for thyroid remnant ablation after thyroid surgery. To date, two different strategies can be used to achieve sufficient TSH stimulation on thyroid remnant: (I) Levo-thyroxine withdrawal or (II) rhTSH stimulation. The aim of our study was to compare the abdominal absorbed dose ratio between differentiated thyroid cancer patients who underwent thyroid remnant ablation after either L-T4 withdrawal or rhTSH stimulation. METHODS: We reviewed the records of 63 patients affected by differentiated thyroid cancer. All patients underwent thyroid remnant ablation after either L-T4 withdrawal or rhTSH stimulation. A post-therapy whole-body scan was obtained 5 days after 131-radioiodine therapy. Qualitative and quantitative image analysis was performed. Quantitative analysis was performed by drawing seven regions of interest on the abdomen (anterior and posterior views) to estimate both the activity ratio (AR) and absorbed dose ratio (DR) obtained in patients treated in hypothyroidism or after rhTSH stimulation. RESULTS: The values of the activity and absorbed dose ratios obtained on each abdomen region (liver, stomach, ascending colon, transverse colon, descending colon, rectum, and small intestine) were always higher in patients treated after L-T4 withdrawal than after rhTSH stimulation with p-values of 0.000, 0.000, 0.001, 0.000, 0.022, 0.007, and 0.002, respectively. CONCLUSIONS: DTC patients treated with 131-radioiodine after rhTSH stimulation have lower abdominal radioiodine activity than hypothyroid patients. Our data could be of practical relevance in terms of patient management. The potential impact on rare radioiodine-related gastrointestinal side effects is to be established in specifically designed prospective studies.
PURPOSE: In DTC patients, 131-radioiodine therapy has routinely been used for many years for thyroid remnant ablation after thyroid surgery. To date, two different strategies can be used to achieve sufficient TSH stimulation on thyroid remnant: (I) Levo-thyroxine withdrawal or (II) rhTSH stimulation. The aim of our study was to compare the abdominal absorbed dose ratio between differentiated thyroid cancerpatients who underwent thyroid remnant ablation after either L-T4 withdrawal or rhTSH stimulation. METHODS: We reviewed the records of 63 patients affected by differentiated thyroid cancer. All patients underwent thyroid remnant ablation after either L-T4 withdrawal or rhTSH stimulation. A post-therapy whole-body scan was obtained 5 days after 131-radioiodine therapy. Qualitative and quantitative image analysis was performed. Quantitative analysis was performed by drawing seven regions of interest on the abdomen (anterior and posterior views) to estimate both the activity ratio (AR) and absorbed dose ratio (DR) obtained in patients treated in hypothyroidism or after rhTSH stimulation. RESULTS: The values of the activity and absorbed dose ratios obtained on each abdomen region (liver, stomach, ascending colon, transverse colon, descending colon, rectum, and small intestine) were always higher in patients treated after L-T4 withdrawal than after rhTSH stimulation with p-values of 0.000, 0.000, 0.001, 0.000, 0.022, 0.007, and 0.002, respectively. CONCLUSIONS: DTC patients treated with 131-radioiodine after rhTSH stimulation have lower abdominal radioiodine activity than hypothyroidpatients. Our data could be of practical relevance in terms of patient management. The potential impact on rare radioiodine-related gastrointestinal side effects is to be established in specifically designed prospective studies.
Authors: R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha Journal: Thyroid Date: 2010-10-29 Impact factor: 6.568
Authors: A Campennì; L Giovanella; A Alibrandi; M Siracusa; R M Ruggeri; S Baldari Journal: Clin Endocrinol (Oxf) Date: 2015-08-10 Impact factor: 3.478
Authors: F Pacini; F Basolo; R Bellantone; G Boni; M A Cannizzaro; M De Palma; C Durante; R Elisei; G Fadda; A Frasoldati; L Fugazzola; R Guglielmi; C P Lombardi; P Miccoli; E Papini; G Pellegriti; L Pezzullo; A Pontecorvi; M Salvatori; E Seregni; P Vitti Journal: J Endocrinol Invest Date: 2018-05-04 Impact factor: 4.256
Authors: F Pacini; P W Ladenson; M Schlumberger; A Driedger; M Luster; R T Kloos; S Sherman; B Haugen; C Corone; E Molinaro; R Elisei; C Ceccarelli; A Pinchera; R L Wahl; S Leboulleux; M Ricard; J Yoo; N L Busaidy; E Delpassand; H Hanscheid; R Felbinger; M Lassmann; C Reiners Journal: J Clin Endocrinol Metab Date: 2005-12-29 Impact factor: 5.958
Authors: Shoba Subramanian; David P Goldstein; Luciana Parlea; Lehana Thabane; Shereen Ezzat; Irada Ibrahim-Zada; Sharon Straus; James D Brierley; Richard W Tsang; Amiram Gafni; Lorne Rotstein; Anna M Sawka Journal: Thyroid Date: 2007-12 Impact factor: 6.568
Authors: C Happel; W T Kranert; D Gröner; B Bockisch; A Sabet; I Vardarli; R Görges; K Herrmann; F Grünwald Journal: Endocrine Date: 2020-03-16 Impact factor: 3.633